NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX): Evaluating Valuation After Q3 Revenue Growth and Operational Improvements
ImmunityBio (IBRX) attracted renewed investor attention after reporting third-quarter results that saw product revenue climb, supported by stronger demand for Anktiva in combination with BCG for NMIBC with CIS. The company also narrowed its net loss year-over-year, a sign that rising sales are helping stabilize its financials.
See our latest analysis for ImmunityBio.
ImmunityBio's operational progress has helped steady some nerves, but momentum in the share price has yet to recover. The stock...